Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.1 (
chymotrypsin
)
10,938
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The ets transcription factor PU.1 is an important regulator of the immunoglobulin heavy chain gene intronic enhancer, or mu enhancer. However, PU.1 is only one component of the large multiprotein complex required for B cell-specific enhancer activation. The transcriptional coactivator
HMG-I(Y)
, a protein demonstrated to physically interact with PU.1, increases PU.1 affinity for the mu enhancer muB element, indicating that
HMG-I(Y)
may play a role in the transcriptionally active mu enhanceosome. Increased PU.1 affinity is not mediated by
HMG-I(Y)
-induced changes in DNA structure. Investigation of alternative mechanisms to explain the
HMG-I(Y)
-mediated increase in PU.1/mu enhancer binding demonstrated, by trypsin and
chymotrypsin
mapping, that interaction between PU.1 and
HMG-I(Y)
in solution induces a structural change in PU.1. In the presence of
HMG-I(Y)
and wild-type mu enhancer DNA, PU.1 becomes more
chymotrypsin
resistant, suggesting an additional change in PU.1 structure upon
HMG-I(Y)
-induced PU.1/DNA binding. From these results, we suggest that increased DNA affinity under limiting PU.1 concentrations is mediated by an
HMG-I(Y)
-induced structural change in PU.1. In functional assays,
HMG-I(Y)
further augments transcriptional synergy between PU.1 and another member of the ets family, Ets-1, indicating that
HMG-I(Y)
is a functional component of the active enhancer complex. These studies suggest a new mechanism for
HMG-I(Y)
-mediated coactivation;
HMG-I(Y)
forms protein-protein interactions with a transcription factor, which alters the three-dimensional structure of the factor, resulting in enhanced DNA binding and transcriptional activation. This mechanism may be important for transcriptional activation under conditions of limiting transcription factor concentration, such as at the low levels of PU.1 expressed in B cells.
...
PMID:PU.1-mediated transcription is enhanced by HMG-I(Y)-dependent structural mechanisms. 1112 59